Diquafosol Tetrasodium

地夸磷索钠

Report date: 2026/03/09 20:02:04
NMEFirst In Class

Base Information

Drug NameDiquafosol Tetrasodium
Drug Alias NameDiquafosolum二尿嘧啶核苷四聚磷酸酯四钠盐Dicuafosol地夸磷索四钠地夸磷索 +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPurinergic receptor P2Y2 agonists
TargetsPurinergic receptor P2Y2
Therapy Area/IndicationsDry Eye SyndromesXerophthalmiaKeratoconjunctivitis Sicca
Global Approved IndicationsXerophthalmia
Approved Indications in ChinaXerophthalmia
Original Approved Country/TerritoryJapan
Original Approved Date2010/04/16
Country/TerritoryTaiwanSouth KoreaIndonesia +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanten Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTaejoon Pharmaceutical Co LtdSanten Pharmaceutical Co LtdIndonesia University +[4] 
Inactive CompaniesMerck Sharp & Dohme LLC
Active IndicationsDry Eye SyndromesXerophthalmia
Inactive IndicationsKeratoconjunctivitis Sicca

Other Information

ATC CodeS02AA
Related LinksWikipediaKEGG